MBCproject_0107_T1_RNA
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.340
- TGF_BETA_SIGNALING+0.320
- E2F_TARGETS+0.310
- MYC_TARGETS_V1+0.300
- TNFA_SIGNALING_VIA_NFKB+0.260
- MYC_TARGETS_V2+0.250
- UNFOLDED_PROTEIN_RESPONSE+0.190
- UV_RESPONSE_DN+0.180
- G2M_CHECKPOINT+0.170
- DNA_REPAIR+0.150
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.430
- ALLOGRAFT_REJECTION-0.280
- HYPOXIA-0.250
- WNT_BETA_CATENIN_SIGNALING-0.240
- KRAS_SIGNALING_DN-0.230
- COAGULATION-0.220
- MYOGENESIS-0.220
- P53_PATHWAY-0.200
- APICAL_JUNCTION-0.190
- COMPLEMENT-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A25E-01A-11R-A169-07 | — | B | 0.728 |
| 2 | 35f68daa-0cea-40de-99b8-446d9e9784c8 | — | — | 0.691 |
| 3 | MDT-AP-2497 | Med | Medulloblastoma | 0.691 |
| 4 | 9F4AEC07-5C91-4009-BA26-E4947CAA3391 | — | — | 0.689 |
| 5 | MNG1219 | — | — | 0.689 |
| 6 | TCGA-75-6207-01A-11R-1755-07 | — | cohortA1 | 0.680 |
| 7 | DRR168568 | — | — | 0.679 |
| 8 | MDT-AP-3297 | Med | Medulloblastoma | 0.679 |
| 9 | R143 | — | — | 0.678 |
| 10 | SRR12202459 | — | — | 0.676 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.060 | Inavolisib | — uncovered |